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INTRODUCTION 
 
Generic drugs are cost  effective alternatives  for the brand  name drugs and  the savings are 
estimated in the average $8 to $10 billion a year. (Lauren et al., 2009; Information for Consumers). 
Over the years the prescription of generic drugs has increased substantially (1984: 
19% & 2009- 60-70%) (IMS health; Information for consumers). Bioequivalence testing is 
playing a vital role in generic drug development.  The generics have to be developed and tested 
in human subjects   by following stringent GCP/GLP standards. From industry point of view, 
there is a need to conduct bioequivalence studies at an allowable cost to have an effective generic 
development program in a scientifically acceptable standard. In order to achieve this from time 
to time various regulatory agencies have issued guidance’s to bring more clarity and uniformity 
for conducting Bioavailability (BA)/ Bioequivalence (BE) studies. 
 
 
Pharmaceutical companies develop products based on their business plans and development of 
generics for USA and EU gets the priority. In general FDA suggests highest strength as RLD or 
as per individual product recommendations where as for EU generally highest strength or the 
choice should be justified if lower strength is used based on safety, linearity and dose 
proportionality, but for selection of dose and strength one need to depend on the literature but 
lack and validity of the literature (NfG on the Investigation of Bioequivalence- 
CPMP/QWP/EWP/1401/98 Rev. 1). 
 
 
As per the present scenario generic product development by the entrepreneur is carried out for all 
the markets simultaneously in order to reduce cost. Recently EU has come out with a relatively 
better option to reduce the developmental cost of generic product like same test product can be 
compared against two references in a 3 way design, but in case of failure with any one of the 
innovator, industry has to go back to reformulation (NfG on the Investigation of 
Bioequivalence- CPMP/QWP/EWP/1401/98 Rev. 1). 
 
 
 
Development of ANDAs for highly variable drug is the major concern for the generic drug 
industry. Drugs and drug products that exhibit high within-subject variability in Cmax and AUC 
present a challenge for the design of BE studies. For example, a drug with a variability of 50%
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would require a study in 100 subjects to demonstrate the equivalence of the reference to itself. So 
development of study designs that would allow demonstration of bioequivalence with a smaller 
number of subjects was needed. (Marier et al., 2008) 
 
 
Draft EMEA guidance (CHMP- Guideline on the investigation of bioequivalence; 
CPMP/EWP/QWPI1401198 Rev.1:2012) says, 
“In case the pro-drug or active metabolites display non-linear pharmacokinetics, it is 
recommended to demonstrate bioequivalence for the main active metabolite. In such case, the 
parent compound does not need to be measured provided that it is inactive from efficacy and 
safety perspectives.” Based on this studies were conducted on valacyclovir by measuring 
aciclovir. But as per the final guidance EMEA (NfG on the Investigation of Bioequivalence- 
CPMP/\ QWP/EWP/1401/98 Rev. 1), we need to measure parent compound Valaciclovir
1
. 
 
 
 
The BE studies should normally be performed in healthy volunteers unless safety warranties. 
Study in healthy volunteers, is adequate to detect formulation differences and allow extrapolation 
of the results to populations for which the reference product is approved (theelderly, children, 
patients with renal or liver impairment, etc.).  There is a wide experience that two formulations 
that were 
bioequivalent in one study population will also be bioequivalent in other populations (Rhodes, 
 
1995). Generic drug developers are still behind the exact reason for proving BE in special 
population, particularly when it is a crossover design. 
A generic equivalent drug product may be marketed by a drug company only after proving that it 
is bioequivalent to the innovator product. This is true whether a generic company wants to 
register its drug with USFDA and sell it in USA or if it wants to sell it in India.
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As per Food-effect Bioavailability and Fed Bioequivalence guideline 
 
“In addition to  a BE study under  fasting conditions, we recommend a BE study under  fed 
conditions for all orally administered immediate release drug products, with the following 
exceptions: 
• When both test product and RLD are rapidly dissolving, have  similar dissolution profiles, and 
 
Biopharmaceutics Classification System (BCS) Class I or 
 
• When the DOSAGE  AND  ADMINISTRATION section of the RLD  label states that  the 
 
product should be taken only on an empty stomach, or 
 
• When the RLD label does not make any statements about the effect of food on absorption or 
administration.”   (Food-Effect: Guidance for Industry, 2002) 
 
 
 
 
If we tweak our objective that in the global marketplace, all generic, multisource, drug products 
should be bioequivalent and therapeutic equivalent to a single, standard RLD to avoid possible 
significant variations among generic drugs and their brand name counterpart, it could possibly 
reduce the burden of generic entrepreneur. But in order to achieve it we need to come out with a 
universal reference (Leon et al., 2009).
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1.0      General introduction 
 
1.1      BIOAVAILABILITY 
 
To exert an optimal therapeutic action an active moiety should be delivered to its site of action in 
an effective concentration for the desired period. To allow reliable prediction of the therapeutic 
effect  the  performance  of the  dosage  form containing  the  active  substance  should  be  well 
characterized. 
 
Bioavailability (BA)  studies focuses on the process by which the active ingredients or moieties 
are released from an oral dosage form and move to the site of action. BA data provide an 
estimate of the fraction of the drug absorbed, as well as its subsequent distribution and elimination. 
 
BA can be generally documented by a systemic exposure profile obtained by measuring drug 
and/or metabolite concentration in the systemic circulation over time. The systemic exposure 
profile determined during clinical trials in the Investigational New Drug (IND) period can serve 
as a benchmark for subsequent BE studies. 
 
Bioavailability is defined as the rate and extent to which the active ingredient, or active moiety, 
is absorbed from a drug product, and becomes available at the site of action. For drug products 
that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by 
measurements intended to reflect the rate and extent to which the active ingredient or active moiety 
becomes available at the site of action. 
 
From a pharmacokinetic (PK) perspective, BA data for a given formulation provides an estimate 
of the relative fraction of the orally administered dose that is absorbed into the systemic circulation 
when compared to the BA data for a solution, suspension, or intravenous dosage form. In 
addition, BA studies provide other useful pharmacokinetic information related to distribution, 
elimination, the effects of nutrients on absorption of the drug, dose proportionality, linearity in 
pharmacokinetics of the active moieties and, where appropriate, inactive moieties. BA data may 
also provide information indirectly about the properties of a drug substance before entry  into  the  
systemic  circulation,  such  as  permeability  and  the  influence  of  presystemic enzymes and/or 
transporters (e.g., p-glycoprotein).
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Systemic exposure patterns reflect both release of the drug substance from the drug product and 
a series of possible presystemic/systemic actions on the drug substance after its release from the 
drug product. 
 
Comparative studies are performed to understand the relative contribution of these processes to 
the systemic exposure pattern. 
 
Comparison of therapeutic performances of two medicinal products containing the same active 
substance is a critical means of assessing the possibility of alternative use between the innovator 
and any essentially similar medicinal product. Assuming that in the same subject an essentially 
similar plasma concentration time course will result in essentially similar concentrations at the 
site of action and thus in an essentially similar effect, pharmacokinetic data instead of therapeutic 
results may be used to establish equivalence – bioequivalence2. 
 
 
In vivo performance, in terms of BA/BE, may be considered to be one aspect of product quality 
that provides a link to the performance of the drug product used in clinical trials, and to the 
database containing evidence of safety and efficacy. 
 
Studies to measure BA and/or establish BE of a product are important elements in support of 
Investigational New Drugs (INDs), New Drug Applications (NDAs), Abbreivated New Drug 
Applications (ANDAs), and their supplements. 
 
1.2      BIOEQUVILANCE 
 
Bioequivalence gained increasing attention during the last 40 years after it became evident that 
generic product  and  innovator  product,  having  the same amounts of the drug,  may exhibit 
marked differences in their therapeutic responses. 
 
Nowadays Bioequivalence studies are a pivotal part of registration dossiers. These studies measure 
the bioavailability of two (or more) formulations of the same active ingredient. The purpose of the 
study is that the bioavailability of the formulations under investigation is shown to be equal. Based 
on that conclusion, one may subsequently claim that the therapeutic quality of these formulations 
is identical. The latter means that both the beneficial and side effects are identical and hence the 
formulations are interchangeable.
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Bioequivalence studies compare both the rate and extent of absorption of various multisource 
formulations with the innovator (reference) product, on the basis that if two formulations exhibit 
similar drug concentration-time profiles in the blood/plasma, they should exhibit similar 
therapeutic effects. 
 
Bioequivalent simply means that one brand or dosage form of a drug or supplement is equivalent 
to  a reference  brand  or  dosage  form of the  same  drug  or  supplement  in  terms  of various 
bioavailability parameters measured via in vivo testing in human subjects. A product can be 
either bio-equivalent or bio-in equivalent. A product cannot be more bio-equivalent or less bio- 
equivalent. 
 
Two medicinal products containing the same active substance are considered bioequivalent if 
they are pharmaceutically equivalent or pharmaceutical alternatives and their bioavailabilities 
(rate and extent) after administration in the same molar dose lie within acceptable predefined limits. 
These limits are set to ensure comparable in vivo performance, i.e. similarity in terms of safety and 
efficacy. 
 
In bioequivalence studies, the plasma concentration time curve is generally used to assess the 
rate and extent of absorption. Selected pharmacokinetic parameters and preset acceptance limit s 
allow the final decision on bioequivalence of the tested products. 
 
    AUC, the area under the concentration time curve, reflects the extent of exposure. 
 
     Cmax, the maximum plasma concentration or peak exposure, and 
 
  Tmax, the time to maximum plasma concentration, are parameters that are influenced by 
absorption rate. (EMEA) 
 
Bioequivalence is defined as: 
 
 
the absence of a significant difference in the rate and extent to which the active ingredient or active 
moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site 
of drug action when administered at the same molar dose under similar conditions in an 
appropriately designed study.
AN OPEN LABEL TWO WAY TWO PERIOD RANDOMISED SINGLE DOSE COMPARITIVE ORAL BIOAVAILABILITY STUDY OF 
ZAFIRLUKAST IN HEALTHY VOLUNTEERS UNDER FASTING CONDITIONS 
7 
 
 
 
 
On the basis of simple pharmacokinetic concepts and parameters, bioavailability and 
bioequivalence   studies   have   been   established   as   acceptable   surrogates   for   expensive, 
complicated and lengthy clinical trials, and are used extensively worldwide to establish and 
ensure  consistent  quality  and  a  reliable,  therapeutically  effective  performance  of  marketed 
dosage forms. 
 
 
 
 
1.3      Role of BE in drug development 
 
1.   IND (INVESTIGATIONAL NEW DRUG)/NDAs( NEW DRUG 
APPLICATIONS 
 
BE documentation can be useful during the IND or NDA period to establish links between (1) 
early and late clinical trial formulations; (2) formulations used in clinical   trial and stability 
studies, if different; (3) clinical trial formulations and to-be-marketed drug product; and (4) other 
comparisons, as appropriate. 
 
In each comparison, the new formulation or new method of manufacture is the t est product and 
the prior formulation or method of manufacture is the reference product. 
 
A test product can fail to meet BE limits because the test product has higher or lower measures 
of rate and extent of absorption compared to the reference product or because the performance of 
the test or reference product is more variable. 
 
2. ANDAs (ABBRIEVATED NEW DRUG APPLICATIONS) 
 
 
BE studies are a critical component of ANDA submissions. The purpose of these studies is to 
demonstrate BE between a pharmaceutically equivalent generic drug product and the 
corresponding reference listed drug. Together with the determination of pharmaceutical 
equivalence, establishing BE allows a regulatory conclusion of therapeutic equivalence. 
 
3. Postapproval Changes
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For approved NDAs, we also recommend that the drug product after the change be compared to 
the drug product before the change. For approved ANDAs, we also recommend that the drug 
product after the change be compared to the reference listed drug. 
 
Three situations have been defined in which bioequivalence studies are required 
 
 
 When the proposed marketed dosage form is different from that used In pivotal clinical 
trials, 
 
    When significant changes are made in the manufacture of the marketed formulation, and 
 
    When a new generic formulation is tested against the innovator’s marketed product. 
Bioequivalence  studies  impact  of changes  to  the  dosage  form process  after  pivotal studies 
commence to ensure product on the market is comparable to that upon which the efficacy is 
based 
 
  Establish that a new formulation has therapeutic equivalence in the rate and extent of 
absorption to the reference drug product. 
  Important for linking the commercial drug product to clinical trial material at time of 
 
NDA 
 
  Important for post-approval changes in the marketed drug formulation 
 
 
 
 
 
Once bioequivalence is established between two products the concept of prescribability and 
switchability comes into picture. These are concepts about the ease with which the physician can 
prescribe the generic product or the innovator product depending on various factors. 
 
Drug prescribability is defined as the physician's choice for prescribing an appropriate drug 
product for his/her new patients between a brand-name drug product and a number of generic 
drug products of the brand-name product, which have been shown to be bioequivalent to the 
brand-name drug product. The underlying assumption of drug prescribability is that the brand- 
name drug product and its generic copies can be used interchangeably in terms of the efficac y 
and safety of the drug product.
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Drug switchability is related to the switch from a drug product (eg, a brand-name drug product) 
to an alternative drug product (eg, a generic copy of the brand-name drug product) within the same 
subject whose concentration of the drug product has been titrated to a steady, efficacious, and safe 
level. As a result, drug switchability is considered more critical than drug prescribability in the 
study of drug interchangeability for patients who have been on medication for a while. To assure 
drug switchability, it is recommended that bioequivalence be assessed within individual subjects. 
This type of bioequivalence is known as individual bioequivalence (IBE). 
 
New drug 
 
A new drug means and include 
 
(a) A drug, as defined in the Act including bulk drug substance which has not been used in the 
country to any significant extent under the conditions prescribed, recommended or suggested in 
the labelling thereof and has not been recognized as effective and safe by the licensing authority. 
 
(b)  A drug  already approved  by the Licensing  Authority for  certain  claims,  which  is  now 
proposed to be marketed with modified or new claims, namely, indications, dosage, dosage form 
(including sustained release dosage form) and route of administration. 
 
(c) A fixed dose combination of two or more drugs, individually approved earlier for certain 
claims, which are now proposed to be combined for the first time in a fixed ratio, or if the ratio 
of ingredients in an already marketed combination is proposed to  be changed, with certain 
claims, viz. indications, dosage, dosage form (including sustained release dosage form) and route 
of administration. 
 
(i) All vaccines shall be new drugs unless certified otherwise by the Licensing Authority. 
 
(ii) A new drug shall continue to be considered as new drug for a period of four years from the 
date of its first approval or its inclusion in the Indian Pharmacopoeia, whichever is earlier. 
 
Generic drug 
 
 
Generic drugs are safe and effective alternatives to brand name prescriptions. Generic drugs can 
help both consumers and the government to reduce the cost of prescription drugs.
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The term “generic product” it means a pharmaceutical product, usually intended to be 
interchangeable with the innovator product, which is usually manufactured without a license 
from the innovator company and marketed after expiry of patent or other exclusivity rights. 
 
Pharmaceutical equivalents means drug products that contain identical amounts of the identical 
active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, in identical 
dosage forms, but not necessarily containing the same inactive ingredients, and that meet the 
identical ingredients or other applicable standard of identity, strength, quality, and purity, including 
potency and, where applicable, content uniformity, disintegration times and/or dissolution rates. 
 
Pharmaceutical alternatives means drug products that contain the identical therapeutic moiety, 
or its precursor, but not necessarily in the same amount or dosage form or as the same salt or 
ester. Each such drug  product  individually  meets either  the  identical or  its own respective 
compendia  or  other  applicable  standard  of  identity,  strength,  quality,  and  purity,  including 
potency and, where applicable, content uniformity, disintegration times and/or dissolution rates. 
 
Innovator product 
 
 
The innovator product is that which was authorized for marketing (normally as a patented 
drug) on the basis of documentation of efficacy, safety and quality (according to 
contemporary requirements). 
  No clinical studies have been performed in patients with the Generic Product to 
support its Efficacy and Safety. 
  With data to support similar in vivo performance (= Bioequivalence) efficacy and 
safety data can be extrapolated from the innovator product to the generic product 
3
. 
 
1.4      CLINICAL TRIAL 
 
“Clinical trial” means a systematic study of new drug(s) in human subject(s) to generate data for 
discovering  and/or  verifying  the  clinical,  pharmacological (including  pharmacodynamic  and 
pharmacokinetic)  and  /or  adverse effects with the objective of determining  safety and  /  or 
efficacy of the new drug. 
 
PHASES OF CLINICAL TRIAL
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Human Pharmacology (Phase I): 
 
 
(i) The objective of studies in this Phase is the estimation of safety and tolerability with the 
initial administration of an investigational new drug into human(s). Studies in this Phase of 
development  usually  have  non-therapeutic  objectives  and  may  be  conducted  in  healthy 
volunteers subjects or certain types of patients. Drugs with significant potential toxicity e.g. 
cytotoxic drugs are usually studied in patients. Phase I trials should preferably be carried out by 
Investigators trained in clinical pharmacology with access to the necessary facilities to closely 
observe and monitor the Subjects. 
 
(ii) Studies conducted in Phase I, usually intended to involve one or a combination of the 
following objectives:- 
 
(a) Maximum tolerated dose: To determine the tolerability of the dose range expected to be needed 
for later clinical studies and to determine the nature of adverse reactions that can be expected. 
These studies include both single and multiple dose administration. 
 
(b) Pharmacokinetics, i.e., characterization of a drug's absorption, distribution, metabolism and 
excretion. Although these studies continue throughout the development plan, they should be 
performed to support formulation development and determine pharmacokinetic parameters in 
different age groups to support dosing recommendations. 
 
(c) Pharmacodynamics: Depending on the drug and the endpoints studied, pharmacodynamic 
studies and studies relating to drug blood levels (pharmacokinetic/ pharmacodynamic studies) 
may be conducted in healthy volunteer Subjects or in patients with the target disease. If there are 
appropriate  validated  indicators  of  activity  and  potential  efficacy,  pharmacodynamic  data 
obtained from patients may guide the dosage and dose regimen to be applied in later studies. 
 
(d) Early Measurement of Drug Activity: Preliminary studies of activity or potential therapeutic 
benefit  may be  conducted  in  Phase  I  as a  secondary objective.  Such  studies  are  generally 
performed in later Phases but may be appropriate when drug activity is readily measurable with a 
short duration of drug exposure in patients at this early stage. 
 
Therapeutic exploratory trials (Phase II):
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(i) The primary objective of Phase II trials is to evaluate the effectiveness of a drug for a 
particular indication or indications in patients with the condition under study and to determine 
the common short-term side-effects and risks associated with the drug. Studies in Phase II should 
be conducted in a group of patients who are selected by relatively narrow criteria leading to a 
relatively homogeneous population. These studies should be closely monitored. An important 
goal for this Phase is to determine the dose(s) and regimen for Phase III trials. Doses used in 
Phase II are usually (but not always) less than the highest doses used in Phase I. 
 
(ii) Additional objectives of Phase II studies can include evaluation of potential study endpoints, 
therapeutic  regimens  (including  concomitant  medications)  and  target  populations  (e.g.  mild 
versus severe disease) for further studies in Phase II or III. These objectives may be served by 
exploratory analyses, examining subsets of data and by including multiple endpoints in trials. 
 
(iii) If the application is for conduct of clinical trials as a part of multi-national clinical 
development of the drug, the number of sites and the patients as well as the justification for 
undertaking such trials in India shall be provided to the Licensing Authority. 
 
Therapeutic confirmatory trials (Phase III): 
 
 
(i) Phase III studies have primary objective of demonstration or confirmation of therapeutic 
benefit(s). Studies in Phase III are designed to confirm the preliminary evidence accumulated in 
Phase  II  that  a  drug  is  safe  and  effective  for  use  in  the  intended  indication  and  recipient 
population.  These  studies  should  be  intended  to  provide  an  adequate  basis  for  marketing 
approval. Studies in Phase III may also further explore the dose-response relationships 
(relationships among dose, drug concentration in blood and clinical response), use of the drug in 
wider  populations,  in different  stages of disease, or the safety and  efficacy of the drug  in 
combination with other drug(s). 
 
(ii) For drugs intended to be administered for long periods, trials involving extended exposure to 
the drug are ordinarily conducted in Phase III, although they may be initiated in Phase II. These 
studies carried out in Phase III complete the information needed to support adequate instructions 
for use of the drug (prescribing information).
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(iii) For new drugs approved outside India, Phase III studies need to be carried out primarily to 
generate  evidence  of  efficacy  and  safety  of  the  drug  in  Indian  patients  when  used  as 
recommended in the prescribing information. Prior to conduct of Phase III studies in Indian 
subjects, Licensing Authority may require pharmacokinetic studies to be undertaken to verify 
that the data generated in Indian population is in conformity with the data already generated 
abroad. 
 
(iv) If the application is for the conduct of clinical trials as a part of multi-national clinical 
development  of the  drug,  the  number  of sites  and  patients  as  well  as  the  justification  for 
undertaking such trials in India should be provided to the Licensing Authority along with the 
application. 
 
Post Marketing Trials (Phase IV): 
 
 
Post Marketing trials are studies (other than routine surveillance) performed after drug approval 
and related to the approved indication(s). These trials go beyond the prior demonstration of the 
drug’s safety, efficacy and dose definition. These trials may not be considered necessary at the 
time of new drug approval but may be required by the Licensing Authority for optimizing the 
drug's use. They may be of any type but should have valid scientific objectives. Phase IV trials 
include additional drug-drug interaction(s), dose-response or safety studies and trials designed to 
support use under the approved indication(s), e.g. mortality/morbidity studies, epidemiological 
studies etc
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2.0      AN OVERVIEW ABOUT THE DRUG AND ITS USE 
 
2.1       ASTHMA 
 
Asthma is defined as "a chronic inflammatory disorder of the airways by the  Global Initiative for 
Asthma
8
. Bronchial asthma is characterized by hyperresponsiveness of tracheobronchial smooth 
muscle to a variety of stimuli, resulting in narrowing of air tubes, accompanied by increasing 
secretion, mucosal edema and mucus plugging.  Symptoms include dyspnoea, wheezing, and 
cough. 
 
Asthma was recognized to be a primarily inflammatory condition: inflammation underlying 
hyper reactivity. A variety of trigger factors are involved. Common asthma triggers includes 
Dust, cold weather, Chemicals in the air or in food, Exercise, Mold, Pollengrains, Respiratory 
infections such as the common cold, Strong emotions (stress),Tobacco smoke, pet hair. 
 
Asthma is considered as 
 
 
    Extrinsic asthma: it is mostly episodic, less prone to status asthmaticus. 
 
    Intrinsic asthma: it tends to be perennial, status asthmaticus is more common. 
 
 
Mediators like mast cells, eosinophils and inflammatory cells together constrict bronchial smooth 
muscle, cause mucosal edema and all resulting in reversible airway obstruction. Majority of 
asthmatics are atopic. In such atopic subjects, challenge of the airways with allergens to which 
they are sensitive leads to bronchoconstriction
5
.
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Clinical classification of severity 
       
 
Use of short- 
acting 
beta2 agonist 
for symptom 
control (not 
for prevention 
of EIB) 
 
 
Severity in 
patients ≥ 12 
years of age 
 
 
Symptom 
frequency 
 
 
Night time 
symptoms 
 
 
%FEV1 of 
predicted 
 
 
FEV1Variability 
 
   
 
  
 
 
≤2 per week 
 
 
 
≤2 per month 
 
 
 
≥80% 
 
 
 
<20% 
 
 
≤2 days per 
week 
 
 
Intermittent 
 
 
 
Mild 
persistent 
 
 
>2 per week 
but not daily 
 
 
 
3-4 per month 
 
 
 
≥80% 
 
 
 
20–30% 
 
 
>2 days/week 
but not daily 
 
 
Moderate 
persistent 
 
 
 
Daily 
 
 
>1 per week 
but not nightly 
 
 
 
60–80% 
 
 
 
>30% 
 
 
 
Daily 
  
 
 
Throughout 
the day 
 
 
Frequent 
(often 
7x/week) 
 
 
 
 
<60% 
 
 
 
 
>30% 
 
 
 
Several times 
per day 
 
 
Severe 
persistent 
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Bronchial asthma is clinically divided as
6
, 
 
 
1.   Mild intermittent asthma: 
 
This is often a recognizable precipitating factor such as allergy, an upper respiratory tract 
infection or psychological trauma. 
2.   Chronic persistent asthma: 
 
This is generally due to presence of inflammation and thickening of mucosa of 
bronchioles with excessive secretion of mucus. The chronic is divide into mild, moderate 
and severe depending on the interference with dialy activities. In some chronic asthma 
co-exists with COPD. 
 
3.   Severe acute asthma: 
 
It is a condition where acute asthma is severe, persistent, it is accompanied by evidence 
of respiratory insufficiency or failure. 
4.   Exercise-induced asthma: 
 
In this attack is precipitated by exercise or inhalation of cold air.
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3.2 TYPES OF ASTHMA 
Brittle asthma 
 
It is two types of asthma, noticed by recurrent, severe attacks. 
 
    Type 1 brittle asthma shows wide peak flow variability, intense medication. 
 
  Type 2 brittle asthma associated by well-controlled asthma, with sudden 
severe exacerbations. 
 
Asthma attack 
 
It is an acute asthma exacerbation.  shortness of breath, wheezing, and chest tightness are the 
classical symptoms. 
 
The use of accessory muscles (sternodeidomastoid and scalene muscles) of respiration produces 
a pulse that is weaker during inhalation and stronger during exhalation and over-inflation of the 
chest are the symptoms of acute asthma attack. 
 
The peak expiratory flow rate (PEFR) shows in case of 
 
    In a mild exacerbation it is ≥ 200 L/min or  ≥ 50% 
 
    In a moderate it is between 80 and 200 L/min or 25% and 50%. 
 
    In a severe it is  ≤ 80L/min or  ≤ 25%. 
 
Status asthmaticus 
 
It is an acute exacerbation of asthma which does not respond to standard treatments of 
bronchodilators and steroids. Nonselective beta blockers (eg: Timolol) caused fatal status 
asthmaticus. 
 
Exercise induced 
 
The asthma which is common among top athletes. 
 
It is relatively high incidence of asthma occurs  in sports such as 
 
    mountain biking, 
 
    cycling, 
 
     long-distance.
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Occupational 
 
Asthma which shows or associated with the workplace exposures is a commonly known 
occupational asthma or occupational respiratory disorder. 
 
Generally 15–23% of asthma cases in adults are work related according to American thoracic 
society (2004). The occupation like fabricators, operators shows high percentage of work related 
asthma. The manufacturing industries are generally associated with these cases. Others 
like animal proteins, natural rubber, and certain reactive chemicals also causes occupational 
asthma
7
. 
 
PRINCIPLES OF THERAPY: 
 
Generally treatment include 
 
    Relieving bronchospasm 
 
    Reducing the inflammation 
 
The available therapeutic measures are: 
 
    Elimination of trigger factors: eg., allergens, environmental pollution 
 
    Avoiding respiratory irritants: eg., smoking 
 
    Drug therapy: use of bronchodialators and anti-inflammatory drugs 
 
    Correction of dehydration and acidosis in severe acute attack. 
 
    Controlled administration of oxygen 
 
    Physical exercise 
 
    Psychological treatment.
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3.3   EPIDEMIOLOGY 
 
Asthma is major health problem across worldwide. In developed and westernized countries show 
high rates of asthma. Asthma shows 7-10% across world wide. Symptoms were more prelevant 
in United Kingdom, Australia, Newzealand and lowest in eastern Europe, Greece, India. 
 
Asthma nearly affects 15 million Americans, in this mostly 5 millions are  children. The cases of 
asthma were increased. The lifestyle and environmental hypothesis showed increase rates of 
asthma. Death rates are mostly higher among African Americans than among white Americans. 
It is more common in boys than girls. It is also common in women than men. Between 1960s and 
 
2008, death rates were increased. In most countries, asthma thought to affect 3% of population. 
 
 
Although genetic predisposition is clearly evident, gene by- environment interaction probably 
explains much of the international variation in prevalence rates for allergy and asthma. 
Environmental factors such as infections and exposure to endotoxins may be protective or may 
act as risk factors, depending in part on the timing of exposure in infancy and childhood. Some 
prenatal risk factors, including maternal smoking which been firmly established, but diet and 
nutrition, stress, use of antibiotics and mode of delivery may also affect the early development of 
allergy and  asthma.  Later  in childhood,  putative risk  factors include exposure to  allergens, 
breastfeeding (which may initially protect and then increase the risk of sensitization), family size 
and structure, and sex and gender. In adulthood, recurrence of childhood asthma may be just as 
common as new-onset asthma. 
The examination of epidemiologic risk factors in the development of asthma presented here 
began in 2004 with a search of MEDLINE, using the Medical Subject Heading (MeSH) terms 
“asthma,” “longitudinal” and “cohort study.”10
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Cross-sectional population-based studies such as these are highly dependent on recognition of 
symptoms, so they do not necessarily reflect the true heterogeneity of asthma. However, a wide 
variation in prevalence rates has been documented: 
studies  of both  children  and  adults  have  revealed  low  prevalence  rates  (2%–4%)  in  Asian 
countries  (especially  China  and  India)  and  high  rates  (15%–20%)  in  the  United  Kingdom, 
Canada, Australia, New Zealand and other developed countries. 
 
 
This figure shows changes in prevalence of diagnosed asthma (A) and asthma symptoms (B) 
 
over time among children and young adults
11
. 
 
Asthma comprises a range of heterogeneous phenotypes that differ in presentation, etiology and 
pathophysiology. The risk factors for each recognized phenotype of asthma include genetic, 
environmental and host factors. Although a family history of asthma is common, it is neither 
sufficient nor necessary for the development of asthma.
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3.4 CLASSIFICATION OF ANTI ASTHMATIC DRUGS
15
 
 
 
 
  β – Adrenergic Receptor Agonists 
 
  Short acting β – Adrenergic Receptor Agonists 
 
    Albuterol (proventi, ventolin) 
 
    Levabuterol (xopenex, ( R )- enantiomer of albuterol. 
 
    Metaproterenol (alupent) 
 
    Terbutaline (brethaire) 
 
    Pirbuterol (maxair) 
 
  Long acting β – Adrenergic Receptor Agonists 
 
    Salmeterol xinafoate (serevent) 
 
  Oral therapy with β – Adrenergic Receptor Agonists. 
 
 
 
   Glucocorticoids 
 
  Systemic glucocorticoids 
 
  Inhaled glucocorticoids 
 
    Beclamethasone  dipropionate (beclovent) 
 
    Triamacinolone acetonide (azmacort) 
 
    Flunisolide (aerobid) 
 
    Budenoside (pulmicort) 
 
    Fluticasone propionate (flovent) 
 
 
 
 
 
  Leukotriene Receptor antagonists 
 
  Zafirlukast (accolate ) 
 
  M o n t e l u k a s t  (Accolate) 
 
 
 
  Leukotriene synthesis inhibitors 
 
  Zileuton (zyflo)
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  Others  
 
  Cromolyn sodium 
 
  Nedocromil sodium 
 
  Theophylline
 
 
 
  Anticholinergic agents 
 
  Ipratropium bromide (atrovent) 
 
 
 
 
 
ZAFIRLUKAST 
 
3.5 MECHANISM OF THE ACTION 
 
Cystenyl leukotrienes are important mediators of bronchial asthma. 
 
 
Zafirlukast is the leukotriene antagonist, which competitively antagonise cysteinyl leukotriene 
receptor CysLT1 in the lungs which mediates  bronchoconstriction, increased vascular 
permeability and recruitment of eosinophils and results in less inflammation. 
 
Zafirlukast is generally indicated for prophylactic therapy of mild to moderate asthma as 
alternative to inhaled glucocorticoids.
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3.6 PHARMACOKINETICS 
 
The pharmacokinetics of Zafirlukast is as follows: 
 
Absorption 
 
 
Zafirlukast is rapidly absorbed following oral administration. After administration of the 10-mg 
film-coated tablet to fasted adults, the mean peak Zafirlukast plasma concentration (Cmax) is 
achieved in 3 to 4 hours (Tmax). The mean oral bioavailability is 64%. The oral bioavailability 
and Cmax are not influenced by a standard meal in the morning. 
 
The safety and efficacy of ACCOLATE in patients with asthma were demonstrated in clinical 
trials in which the 10-mg film-coated tablet and 5-mg chewable tablet formulations were 
administered in the evening without regard to the time of food ingestion. The safety of 
ACCOLATE in patients with asthma was also demonstrated in clinical trials in which the 4-mg 
chewable tablet and 4-mg oral granule formulations were administered in the evening without 
regard to the time of food ingestion. The safety and efficacy of ACCOLATE in patients with 
seasonal allergic rhinitis were demonstrated in clinical trials in which the 10-mg film-coated 
tablet was administered in the morning or evening without regard to the time of food ingestion. 
 
Distribution 
 
 
Zafirlukast is more than 99% bound to plasma proteins. The steady state volume of distributio n 
of Zafirlukast averages 8 to 11 liters. Studies in rats with radiolabeled Zafirlukast indicate minimal 
distribution across the blood-brain barrier. In addition, concentrations of radiolabeled material at 
24 hours postdose were minimal in all other tissues. 
 
Metabolism 
 
 
Zafirlukast is extensively metabolized. In studies with therapeutic doses, plasma concentrations 
of metabolites of Zafirlukast are undetectable at steady state in adults and pediatric patients.
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In vitro studies using human liver microsomes indicate that cytochromes P450 3A4 and 2C9 are 
involved in the metabolism of Zafirlukast. Clinical studies investigating the effect of known 
inhibitors of cytochromes P450 3A4 (e.g., ketoconazole, erythromycin) or 2C9 (e.g., 
fluconazole) on Zafirlukast pharmacokinetics have not been conducted. Based on further in vitro 
results in human liver microsomes, therapeutic plasma concentrations of Zafirlukast do not 
inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. In vitro studies have shown that 
Zafirlukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-
drug interaction study involving Zafirlukast and rosiglitazone (a probe substrate representative of 
drugs primarily metabolized by CYP2C8) demonstrated that Zafirlukast does not inhibit 
CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized 
by this enzyme. 
 
Elimination 
 
 
The plasma clearance of Zafirlukast averages 45 mL/min in healthy adults. Following an oral dose 
of radiolabeled Zafirlukast, 86% of the radioactivity was recovered in 5-day fecal collections and 
<0.2% was recovered in urine. Coupled with estimates of Zafirlukast oral bioavailability, this 
indicates that Zafirlukast and its metabolites are excreted almost exclusively via the bile. 
 
In several studies, the mean plasma half-life of Zafirlukast ranges from 2.7 to 5.5 hours in healthy 
young adults. The pharmacokinetics of Zafirlukast are nearly linear for oral doses up to 
50 mg. There is little accumulation of the parent drug in plasma (14%), during once-daily dosing 
with 10-mg Zafirlukast. 
 
Drug Interactions 
 
Zafirlukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state: 
 
 did not cause clinically significant changes in the kinetics of a single intravenous dose of 
theophylline (predominantly a cytochrome P450 1A2 substrate).
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     did not change the pharmacokinetic profile of warfarin (primarily a substrate of CYP 
 
2C9, 3A4 and 1A2) or influence the effect of a single 30-mg oral dose of warfarin on 
prothrombin time or the INR (International Normalized Ratio). 
 did not change the pharmacokinetic profile or urinary excretion of immunoreactive 
digoxin. 
 did not change the plasma concentration profile of terfenadine (a substrate of CYP 3A4) 
or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval 
following co-administration with terfenadine 60 mg twice daily. 
 
Indications and usage 
 
 
ACCOLATE is indicated for the 
 
 
 prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of 
age and older. 
    prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. 
 
  relief of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years 
of age and older, and perennial allergic rhinitis in adults and pediatric patients (6 months 
of age and older). 
 
CONTRAINDICATIONS 
 
Hypersensitivity
13
.
AN OPEN LABEL TWO WAY TWO PERIOD RANDOMISED SINGLE DOSE COMPARITIVE ORAL BIOAVAILABILITY STUDY OF 
ZAFIRLUKAST IN HEALTHY VOLUNTEERS UNDER FASTING CONDITIONS 
27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PLAN OF WORK 
 
 
 
 
STUDY OBJECTIVES 
 
The basic aim of this project was to study the conductance of BE study, in accordance 
with the regulatory guidelines. The BE study was conducted on a test product, Zafirlukast and a 
reference product singuliar. 
 
The study objectives included: 
 
 
i. Assessment of the bioavailability of test product A while comparing with a reference 
product B in 12 healthy, normal, adult, human subjects under fasting conditions. 
ii.      Investigate the source of the observed variability in the Cmax of Test drug.
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DESIGN AND CONDUCT OF STUDY 
 
A bioequivalence study is basically a comparative bioavailability study designed to establish 
equivalence between test and reference products. 
 
The design should be based on a reasonable knowledge of the pharmacodynamics and/or the 
pharmacokinetics of the active substance in question. The design and conduct of the study should 
follow ICH/ EU-regulations on Good Clinical Practice, including reference to an Ethics 
Committee. The rights, safety, and well being of all trial subjects must always be respected and 
should be given special attention. 
 
Study Design 
 
The study should be designed in such a way that the formulation effect can be distinguished from 
other effects. If the number of formulations to be compared is two, a two -period, two-sequence 
crossover design is often considered to be the design of choice. 
 
However, under certain circumstances and provided the study design and the statistical analyses 
are scientifically sound alternative well-established designs could be considered such as parallel 
design for very long half-life substances and replicate designs for substances with highly variable 
disposition 
 
In general, single dose studies will suffice, but there are situations in which steady-state studies 
may be required, e.g. in the case of 
 
    dose- or time-dependent pharmacokinetics, 
 
    some modified release products (in addition to single dose investigations), 
or can be considered,
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e.g. 
 
 
 if   problems   of   sensitivity   preclude   sufficiently   precise   plasma   concentration 
measurements after single dose administration. 
 
 
 if the intra-individual variability in the plasma concentration or disposition precludes the 
possibility of demonstrating bioequivalence in a reasonably sized single dose study and 
this variability is reduced at steady state. 
For several drugs a great inter-subject variability in clearance is observed. The intra-subject 
coefficient of variation (approximately 15%) is usually substantially smaller than that between 
subjects (approximately 30%), and therefore, crossover designs are generally recommended for 
bioequivalence studies. 
 
The primary advantage of the crossover design is that since the treatments are compared on the 
same subject, the intersubject variability does not contribute to the error variability. 
 
Inherent in both the crossover and parallel designs are the two fundamental statistical concepts of 
study design, namely 
 
1.   Randomization, 
 
2.   Replication and Error control. 
 
 
 
 
Randomization implies allocation of treatments to the subjects without selection bias. 
Consequently, randomization is essential to determine an unbiased estimate of the treatment 
effects. 
 
In the present study the randomization schedule was generated using the PROC PLAN procedure 
on statistical package SAS, version 9.1. All the subjects were randomly assigned either of the 
two treatment sequences i.e. “AB” or “BA”. The randomization schedule was balanced over the 
period and sequence and all the subjects were dosed, in each period, as per the randomization 
schedule.
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Replication implies that a treatment is applied to more than one experimental unit (subject) to 
obtain more reliable estimates than is possible from a single observation and hence provides a 
more precise measurement of treatment effects. The number of replicates (samp le size) required 
depends upon the degree of differences to be detected and inherent variability of the data. 
 
 
 
 
Replication is used concomitantly with “Error control” to reduce the experimental error or error 
variability. 
 
In the present study the design followed was single dose, open-label, analyst-blind, two- treatment, 
two-period, two-sequence, crossover bioequivalence study. 
 
It is an open labeled study as the subjects and the investigator were not be blinded towards the 
identity of the study medications.  Only the analysts were blinded towards identity of study 
medication administered. 
 
Washout Period 
 
Subsequent treatments should be separated by periods long enough to eliminate the previous 
dose before the next one (adequate wash out periods). In steady-state studies wash out of the 
previous treatment last dose can overlap with the build-up of the second treatment, provided the 
build-up period is sufficiently long (at least three times the terminal half-life). 
 
In the present study drug administration in first period was followed by a washout period of at 
least 7 days before subjects were switched over to the other treatment in the second period. 
 
Selection of subjects: 
 
The subject population for bioequivalence studies should be selected with the aim to minimise 
variability and permit detection of differences between pharmaceutical products. Therefore, the 
studies should normally be performed with healthy volunteers. The inclusion/exclusion criteria 
should be clearly stated in the protocol. Subjects could belong to either sex; however, the risk to 
women of childbearing potential should be considered on an individual basis.
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In general, subjects should be between 18 - 55 years old capable of giving informed consent and 
of weight within the normal range according to accepted normal values for the Body Mass Index 
(BMI) of 18-25. The BMI is calculated using the formula: 
 
 
 
 
 
BM I  
 Weight in Kgs 
Height in m 2 
 
 
 
 
 
 
The number of subjects required is determined by 
 
 the error variance associated with the primary characteristic to be studied as estimated 
from a pilot experiment, from previous studies or from published data, 
    the significance level desired, 
 
 the expected deviation from the reference product compatible with bioequivalence (delta, 
i.e. percentage difference from 100 %)and 
    the required power. 
 
 
 
 
The number of subjects required is calculated by the formula: 
 
 
 
 
 
N=(t, 2N-2+t, 2N-2)
2 
[CV/(V-)]2 
 
 
 
 
 
Where N=number of subjects 
 
 
T=appropriate value from the t-distribution 
 
=type 1 error 
 
 
=type 2 error 
 
 
=Treatment difference
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CV=coefficient of variance (intra subject) 
V=Bioequivalence limit 
Calculations are quite tedious and time consuming, thus it is done using statistical software and 
statistical tools
14
. 
 
Pharmacokinetic Sampling 
 
Under normal circumstances, blood, rather than urine or tissue, should be used. In most cases, 
drug, or metabolites are measured in serum or plasma. However, in certain cases whole blood 
may be more appropriate for analysis. 
 
Blood samples should be drawn at appropriate times to describe the absorption, distribution, and 
elimination phases of the drug. The sampling schedule should be planned to provide an adequate 
estimation of Cmax and to cover the plasma concentration time curve long enough to provide a 
reliable estimate of the extent of absorption. This is generally achieved if the AUC derived from 
measurements is at least 80% of the AUC extrapolated to infinity. For most drugs, 12 to 18 
samples, including a predose sample, should be collected per subject per dose. This sampling should 
continue for at least three or more terminal half lives of the drug. The exact timing for sample 
collection depends on the nature of the drug and the input from the administered dosage form. 
The sample collection should be spaced in such a way that the maximum concentration of the 
drug in the blood (Cmax)  and  terminal elimination rate constant  (z)  can be estimated 
accurately. 
 
For  drugs  with  a  long  half-life,  relative  bioavailability  can  be  adequately  estimated  using 
truncated AUC as long as the total collection period is justified. 
 
According to the Cmax and Tmax values of drug XY, the sampling schedule and amount of blood 
to be collected was decided. 
 
In each period, a total of 18 venous blood samples were collected from each subject as per the 
following schedule: 
 
Predose (00 hr), 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00,   6.00, 8.00, 10.00, 
 
12.00, 16.00, 20.00, 24.00  hrs post dose in each period.
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The total volume of blood collected from each subject during the study will be 250ml for males 
and 258ml for females as follows: 
 
    Pre dose and post-dose samples ( 36 samples of 06 mL each) = 216 mL 
 
 Discarding of saline mixed blood samples resulting from use of intravenous cannula (0.5 
mL each time) = 18 mL 
    Screening and post study laboratory assessments = 16 mL 
 
    Serum pregnancy test (if female) = 8 mL 
 
 
 
DESIGN OF BA/BE FACILITY 
 
A general BE study facility includes various departments like the Clinical department, 
Bioanalytical department, Bio-statistics and Data management division and a Quality assurance 
(QA) department. Each department in turn consists of different functional areas. 
 
The Clinical facility has many subdivisions 
 
  Clinical  Pharmacological  Units  (CPU)  with  areas  for  Phlebotomy,  Dosing  stations, 
recreation and refreshment rooms with safety precautions taken. 
  Separate areas for Pharmacy, sample separation, deep freezers 
 
  Full time medical vigilance and care 
 
  ICU and emergency medical care services 
 
  Diagnostic lab services 
 
  Biowaste disposal services 
 
 
 
The Bioanalytical facility comprises of various functional areas like: 
 
  Analytical lab 
 
  Sample processing room 
 
  Washing room
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  Scientist room 
 
  Store room for chemicals and solvents 
 
  Mass balance room 
 
 
 
 
 
The Biostatistics and Data management division is associated with functions like: 
 
  Sample size calculations 
 
  Statistical analysis 
 
  Study design 
 
  Data collection, verification and analysis 
 
  Report preparation as per the regulatory standards 
 
 
 
Quality  Assurance   department   generally  functions   as   an   independent   unit   for   indirect 
enforcement  of  stringent  quality  standards  to  the  whole  study  process  and  system.  It  is 
responsible for planning and conducting regular audits in all the departments to ensure that all 
the activities are carried out in accordance to the approved protocol, and in accordance with the 
laboratory standards and regulatory. It independently verifies all the raw data generated during 
the study process for its completeness, accuracy and authenticity. 
 
 
CHARACTERISTICS TO BE INVESTIGATED 
 
In most cases evaluation of bioavailability and bioequivalence will be based upon the measured 
concentrations of the parent compound. In some situations, however, measurements of an active 
or inactive metabolite may be necessary instead of the parent compound. The use of a metabolite 
may be advantageous to determine the extent of drug input, e.g. if the concentration of the active 
substance is too low to be accurately measured in the biological matrix (e.g. major difficulty in 
analytical method, product unstable in the biological matrix or half-life of the parent compound 
too short) thus giving rise to significant variability. 
 
In bioavailability studies, the shape of and the area under the plasma concentration versus time 
curves are mostly used to assess extent and rate of absorption. The use of urine excretion data 
may be advantageous in determining the extent of drug input in case of products predominately
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excreted  renally.  From  the  primary  results,  the  bioavailability  characteristics  desired  are 
estimated, namely AUCt, AUC , Cmax, Tmax, Aet, Ae as appropriate, or any other justifiable 
 
 
 
 
 
 
 
characteristics. In bioequivalence studies the AUCt is the most reliable reflection of the extent of 
absorption
15
. 
 
 
 
 
The following pharmacokinetic parameters are required for submission: 
 
 
    Plasma concentrations and time points 
 
    Subject, period, sequence, treatment 
 
    AUC0-t, AUC0-, Cmax, Tmax,z , and t1/2. 
 
    Intersubject, intrasubject, and/or total variability, if available 
 
    Cmin (concentration at the end of a dosing interval), 
 
    Cav (average concentration during a dosing interval), 
 
    Degree of fluctuation [(Cmax-Cmin)/Cav] 
 
 
 
 
The following statistical information required for AUC0-t, AUC0-, and Cmax: 
 
 
    Geometric mean 
 
    Arithmetic mean 
 
    Ratio of means 
 
    Confidence intervals 
 
Rounding off of confidence interval values: 
 
 
Confidence interval (CI) values should not be rounded off; therefore, to pass a CI limit of 80- 
 
125, the value should be at least 80.00 and not more than 125.00.
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CLINICAL COMPONENT 
 
 
 
Communication from Sponsor 
 
Sponsor is an individual, company, institution or organization which takes responsibility 
for the initiation, management, and financing of a clinical study for the veterinary product under 
investigation. The investigator of the study, after receiving infor mation from the sponsor, starts 
preparing the protocol according to which the study is conducted. 
 
 
 
 
Preparation of Protocol 
 
Protocol is defined as a document signed and dated by the investigator and the sponsor that fully 
describes the objective(s), design, methodology, statistical considerations and organization of a 
study. The study protocol may also give the background and rationale for the study but these 
could be provided in other study protocol-referenced documents. 
 
The protocol includes all the details regarding the investigational product, the details regarding 
the administration of the drug, Pharmacokinetic (PK) sample withdrawal time-points, safety 
assessment parameters etc. 
 
A protocol is prepared by the investigators of the study or his designee and reviewed by various 
departments like analytical, statistical, QA to make necessary changes. The following chart gives 
an overview regarding the preparation of the protocol.
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Extensive Literature survey 
 
 
 
 
Preparation of Protocol 
 
 
 
 
Review by Principal Investigator 
 
 
 
 
Circulation of protocol to different departments for review 
 
 
 
 
Inputs from various departments 
 
 
 
 
Revision of the protocol, if necessary, in consultation with the 
 
principal investigator 
 
 
 
 
Sent to the Quality Assurance (QA) department for final review. 
 
 
 
 
Undertake changes given by the QA 
 
 
 
 
Protocol signed by authorized signatory 
 
 
 
 
Approval from the IEC
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Protocol summary: 
 
 
Study title:                   An open label, randomized, two-period, two-sequence, single 
dose Crossover comparative oral bioavailability study of 
Zafirlukast tablet 20 mg (test) of aurobindo pharma ltd and 
Accolate tablets 20 mg (reference) of Merck sharp & Dohme 
ltd, UK in 12 healthy adult, human subjects under fasting 
conditions. 
Study objectives:          To compare the rate and extent of absorption of Zafirlukast 
tablets 10 mg (test) of aurobindo pharma ltd, india with that of 
singuliar tablets 10 mg (reference) of merck sharp and dohme 
ltd, UK. 
To monitor adverse events and to ensure the safety of subjects. 
Study design:                An open label, randomized, two- treatment, two sequence, two 
Period , single dose, comparative oral bioavailability study in 
 
 
12 healthy, adult,  human subjects under fasting conditions. 
Sample size:                  12 healthy, adult human subjects. 
Study treatments:           Reference     :   Accolate 20 mg 
 
 
Test:   Zafirlukast tablets 20 mg. 
 
 
Screening:                       Healthy volunteers aged from 18 years or older with body 
mass index (BMI) between 18.5- 30 kg/m
2 
of either sex males
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or females will be selected according to inclusion and exclusion 
criteria. 
Dose:                                A single oral dose of Zafirlukast tablets 20 mg of reference  and 
test product will be dosed with atleast 150 ml of drinking water 
under fasting conditions. 
Sampling schedule:        At Predose (00 hr), 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 
 
 
4.00, 4.50, 5.00,  6.00, 8.00, 10.00, 12.00, 16.00, 20.00, 24.00 
hrs post dose in each period. 
Blood loss:                     The total volume of blood withdrawn for each subject will be 
 
 
250 for males and 258 for females. 
 
 
Housing:                         Atleast 11 hours before dosing and until 30 hours post dose in 
each period. 
Wash out period:           Atleast 5 days between each treatment schedule. 
Analyte:                         Zafirlukast will be estimated in plasma using a 
validated method. 
 
 
PK parameters &          Tmax, Cmax, AUC0-t, AUC0-α, AUC% extrapolation, Kel  and T1/2 will be 
analysis  :                       determined from Zafirlukast data using 
WIN NONLIN software. 
 
 
Statistical analysis:         Summary statistics, ANOVA, 90% confidence interval, ratio 
analysis, intrasubject variability and power will be caluclated 
for Zafirlukast pharmacokinetic data using SAS
R
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version 9.1.3 at pharmacokinetics and biostatistics unit of 
 
 
APL research centre, Hyderabad, India. 
Bioequivalence criteria:  The test product is considered as bioequivalent to the 
reference product, if 90% confidence interval for ratio of 
population geometric means of Ln-transformed 
parameters Cmax,  AUC0-t and AUC0-α of Zafirlukast is 
within the acceptence interval of 80.00% - 
125.00%. 
 
 
 
 
 
INDEPENDENT ETHICS COMMITTEE 
 
 
Independent Ethics Committee (IEC) consists of a board of members who look into the ethical 
issues of the study to be conducted.  The study operations can be initiated only after the protocol 
is approved by IEC. 
 
An IEC should safeguard the rights, safety, and well  being of all trial subjects. Special attention 
should be paid to trials that may include vulnerable subjects. The investigator may provide 
information on any aspect of the trial, but should not participate in the deliberations of the IEC or 
in the vote/opinion of the IEC. An IEC may invite nonmembers with expertise in special areas 
for assistance. 
 
 
Composition, Functions, and Operations 
 
 
The IEC consists of a reasonable number of members, who collectively have the qualifications 
and experience to review and evaluate the science, medical aspects, and ethics of the proposed 
trial. It is recommended that the IEC should include: at least five members.
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(b) At least one member whose primary area of interest is in a nonscientific area. 
 
 
(c) At least one member who is independent of the institution/trial site. 
 
 
 Only those IEC members who are independent of the investigator and the sponsor of the 
trial should vote/provide opinion on a trial-related matter. 
    A list of IEC members and their qualifications should be maintained. 
 
 It should perform its functions according to written operating procedures, should 
maintain written records of its activities and minutes of its meetings, and should comply 
with GCP and with the applicable regulatory requirement(s). 
 Only members who participate in the IEC review and discussion should vote/provide 
their opinion and/or advise. 
 
 
Protocol Training 
 
After the approval of the protocol, it is discussed among the investigators of the study. The 
summary of the protocol that includes: 
 
 The name of the investigational product (drug to be administered to the subjects), 
Reference drug 
    Dose to be administered 
 
    Type of study whether it is a single center study, a fast or fed study, analyst study etc. 
 
    Number of subjects to be enrolled in the study 
 
 Kind of study etc, and other minute details like the Clinical Pharmacology unit (CPU) in 
which the subjects would be housed etc, 
This summarized version of the protocol is discussed among the personnel in the facility to train 
them in the protocol.
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Registration of Volunteers 
 
For recruiting volunteers for a study suitable volunteers are selected from the database. New people  
are  informed  and  registered  in  the  database  after  the  consent.  Generally,  healthy volunteers 
in the age group of 18-45  years are preferred  based  on inclusion and  exclusion criteria
14
. 
 
 
 
 
Inclusion criteria 
 
 
Subjects must fulfill the following criteria to be considered for inclusion into this study. 
 
 
    Healthy volunteers within age range of 18- 50 yrs. 
 
    A body mass index of 18-25 kg/m2. 
 
    Given written informed consent to participate in the study. 
 
    Absence of disease markers of HIV 1 & 2, hepatitis B & C virus & RPR. 
 
 Absence of significant disease or clinically significant abnormal laboratory values on 
laboratory evaluation, medical history and physical examination during the screening. 
    A normal 12- lead ECG. 
 
    A normal chest X-ray (PA view) 
 
    Compliance with the requirement of the entire protocol. 
 
 No  history  or  no  evidence  of  hypersensitivity  to  Zafirlukast  and  its  formulation 
components. 
    No history of gastrointestinal problems (ulcers) 
 
    No history of significant systemic disorders. 
 
    No history of psychiatric disorders. 
 
    No history of allergic rash. 
 
    No donation of blood (one unit or 350 ml) within 56 days prior to study check-in. 
 
    No history of addiction to any recreational drug or drug dependence. 
 
    No participation in any recreational drug or drug dependence. 
 
    No participation in any clinical study within past 56 days.
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 No receipt of any prescription drugs or over the counter drugs (eg. Cold preparations, 
antacid precipitations, vitamins and natural products used for therapeutic benefits) within 
two weeks prior to study check-in. 
    No history of dehydration from diarrhea, vomiting or any other reason with- in period of 
 
24 hrs prior to study check-in. 
 
    No family history of neurological disorders. 
 
 Not consumed alcohol and xanthine containing food & beverages (chocolates, tea, coffee 
or cola drinks) cigarettes & tobacco products, for atleast 48 hrs prior to study check-in. 
 Not consumed grape fruit ( mosumbi/ sweet lime) juice within 48 hrs prior to study check 
in 
 Negative results for drugs of abuse (benzodiazepines, cocaines, opioids, amphetamines, 
cannabinoids and barbiturates) in urine during the study check-in of each period. 
    Female volunteer demonstrating a negative pregnancy test. 
 
 If study volunteer is female or is of child bearing potential practicing an acceptable 
method of birth control for the duration of study as judged by the investigator(s), such as 
condoms, jellies, foams, diaphragm, intrauterine devices(IUD), or abstinence. 
(Or) 
 
Is postmenopausal for atleast 1 year. 
(Or) 
Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has 
been performed on the study volunteer) 
 
Exclusion criteria 
 
 
The subjects will be excluded based on the following criteria 
 
 
    History of seizures. 
 
    History of alcohol consumption for more than two units / day ( 1 unit = 30 ml of spirit or 
 
1 pint of beer ) or having consumed alcohol within 48 hrs prior to check-in. 
 
 High caffeine ( more than 5 cups of coffee or tea / day )   or tobacco ( more than 9 
cigarettes / beedies / cigars per day) consumption. 
    History of difficulty in donating blood or difficulty in accessibility of veins.
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 An unusual or abnormal diet for whatever reason eg. Because of fasting due to religious 
reasons. 
 Received pharmacological agents known to significantly    induce     or     inhibit     drug 
metabolizing enzymes within 14 days of the start of the study. 
    Female volunteers who are currently breast feeding. 
 
 Female volunteers who has used implanted or injected hormonal contraceptives anytime 
during the 6 months prior to study or used hormonal contraceptives within 14 days 
before dosing. 
 
Withdrawal criteria 
 
 
Subjects may be withdrawn from the study by the principal investigator/ clinical investigator/ 
 
attending physician for any of the following reasons during the course of the study. 
 
 
    If the subject suffers from significant illness. 
 
 After dosing, if the subject vomits, at or before 2 times the median Tmax of Zafirlukast in 
any period. 
    If the subject requires unacceptable concomitant medications. 
 
    If the subject has entered the study in violation of the exclusion and inclusion criteria. 
 
    If the subject found to be non co-operative. 
 
    If the subject decides to voluntarily withdraw from the study. 
 
Note: 
 
Any subject withdrawals will be reported for; 
 
    Reasons for withdrawal ( if any) 
 
 Clinical assessment of the subject will be done at the time of withdrawal if subject 
withdraws during the residential stay. 
 
 
 
 
 
Screening 
 
The registered individuals are screened, by taking their consent. Screening generally includes: 
 
 
    Body mass index (BMI)
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    ECG 
 
    Medical examination that involves general & systemic examination 
 
    Chest X-ray 
 
    Laboratory  tests  including  Hemogram,  liver  function  test  (LFT),  renal  function  test 
 
(RFT), Serology & other details. 
 
 Urine test to determine the consumption of drugs like morphine, codeine, LSD or any 
other drug of abuse (on the day of check in) 
    Breath alcohol test (on the day of check in) 
 
 
 
 
Doctors along with nurses and phlebotomists present  in the facility would be screening the 
volunteers. The volunteers are given a particular date to report to the facility and participate in 
the informed consent session prior to enrollment in the study. 
 
Informed Consent Form (ICF) 
 
Informed Consent is a documented process by which an owner, or owner’s agent, voluntarily 
confirms the owner’s willingness to allow their animal(s) to participate in a particular study, after 
having been informed of all aspects of the study that are relevant to the decision to part icipate. 
 
ICF is designed as per the ICH-GCP and local regulatory requirements. ICF is conducted in 
order to  get the consent  from the volunteer to participate in the study.  It  is conducted  for 
enrollment and general screening of a volunteer. He would be given all the information regarding 
the study including: 
 
    Details of Investigational products 
 
    Adverse events that may occur during the study 
 
    The total blood loss 
 
    The compensation to be given at the end of the study 
 
    Regulations to be followed while participating in the study 
 
He would be given the freedom to withdraw from the study at any point of time, during the 
study. This consent is taken as a part of the ethical issue in conducting a BA/BE study. Every 
care is taken to protect the health of the volunteer. The volunteers would sign on this form and
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give their consent for participating in the study. Once they enroll in to the study, they would be 
 
called ‘subjects’. The enrollment in the study starts in the “check-in” process. 
 
 
 
 
 
 
Check-in Process 
 
The volunteers who gave in their consent to participate in the study would be enrolled in the 
study i.e. the check-in process. During this process it is checked whether the person has met all 
the  inclusion/exclusion  criteria  and  cleared  the  screening  process.  They  will  u ndergo  vital 
examination and Medical examination again to ensure they are fit for participation in the study. 
They would be changing into the uniforms provided to them in the facility. Once the check-in of 
the volunteer is completed he would be called as ‘subject’. The subjects are provided with all the 
requirements they need including recreational activities like movies and games, newspapers. The 
check in day is called as Day 0.The subjects are given standardized dinner after which they will 
be fasting overnight for 10 hours. 
 
 
 
 
Dosing of Investigational product 
 
The subjects are dosed next morning with the investigational product (IP) in the study after they 
have maintained 10hr fasting as per protocol. The dosing day is called as Day 1. Dosing is done 
according to the procedure mentioned in the protocol. The randomization code for the dosing is 
generated by the statistician, in which the sequence of IP administration is mentioned (eg. AB, 
BA). The IP is administered in presence of principal investigator. It is observed that the subject 
takes the IP accordingly with required amount of water and swallows it completely. Once the 
dosing is completed the blood samples (PK samples) from the subject would be collected at time 
intervals mentioned in the protocol. In fed studies high fat breakfast is provided to the subjects 
30  minutes prior to  dosing. One hour predose and 2 hours post  dose water restriction was 
maintained.
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Collection of PK samples 
 
The subjects are cannulated on the day of dosing so that the blood withdrawal would be easier 
and to avoid the repeated needle pricks. Fixed volume of blood (generally 6 ml) is withdrawn at 
each time point. This is collected in the vacutainers containing the adequate amount of 
anticoagulant as per described in the protocol (generally K3 EDTA). To avoid the mixing of the 
 
blood with the residual blood in the cannula 0.5ml blood is discarded before every sample 
collection. After the sample is collected 0.5ml saline will be pushed in the cannula to avoid the 
blockage of the cannula. 
 
The collected blood samples are sent to the separation room where the plasma is separated, after 
centrifugation at defined parameters in the protocol (generally 3000 rpm for 10 minutes) 
 
Safety assessment 
 
To ensure the well being of the subject after the administration of IP, vital signs of the subjects 
are checked at regular intervals of time defined in the protocol. If there is any complaint form the 
subject the Medical officer looks after it and document it as an Adverse event and follow it up till 
the resolution. The normal vital signs range is as follows: 
 
Temperature               97.8 F-99 F 
Pulse Rate                   60-100 beats/min 
Respiration Rate         14-20/min 
Systolic BP                 100-138mm of Hg 
 
 
Diastolic BP               60-88mm of Hg 
 
 
Check out process 
 
After the completion of the study the subjects are checked- out. In the check out process the 
subjects undergo a medical check up to ensure that they are healthy even after participating in the 
study. The study cycle is repeated after the washout period when the subjects are crossed over to 
other treatment. Their post study medical check up includes the blood test. In case of long acting 
drugs the subjects are required to come for ambulatory samples after being checked out of the
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facility. Once the subjects finish giving their PK samples they are paid their compensation as per 
the protocol. 
 
 
 
 
 
 
Sample separation and Storage 
 
The collected PK samples received in vacuettes would be centrifuged at a particular RPM (3000 
rpm) at a temperature of 4 C for around 10-12 minutes. The plasma gets separated due to the 
centrifugal force. This separated plasma is collected in two different tubes called aliquots. The 
aliquots  are  pre-labeled  and  sent  to  the  deep  freezer  where  the  samples  are  stored  at  a 
temperature of –60 C to –70 C. 
 
Various precautions are taken while separating the plasma. The plasma is separated without 
touching the bed of blood cells.  Care should be taken that the samples are not exposed to room 
temperature for a long time. 
 
Every detail regarding the receival of the sample and reporting of hemolysed samples is 
documented in various forms. 
 
Sample Sorting 
 
Once all the samples from the subjects are collected, including the ambulatory samples, the 
samples are sorted. The sorting is done by separating the aliquots containing samples of different 
time points of each subject  into easy sealing bags. Various conditions are maintained while 
sorting the samples, like the maintenance of low temperatures. Sorting is done in presence of dry 
ice to prevent the exposure of samples to room temperature and also to prevent their degradation 
due to thawing. 
 
These bags are sealed into various boxes and stored in the deep freezer, which are later handed 
over to the bio-analytical department with proper documentation for further processing.
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BIOANALYSIS 
 
The bioanalytical part of bioequivalence trials should be conducted according to the 
applicable principles of Good Laboratory Practice (GLP). (EMEA / OECD GLP / WHO GLP 
STANDARD). The bioanalytical methods used to determine the active moiety and/or its 
biotransformation product(s) in plasma, serum, blood or urine or any other suitable matrix must 
be well characterized, fully validated and documented to yield reliable results that can be 
satisfactorily interpreted. 
 
 
 
 
Materials and Methods 
 
The list of materials and methods used during analytical phase of the study are discussed below: 
 
 
 
 
 
Materials 
 
Table No. 1: Investigational Products: 
 
 
Product Dose 
 
Test product A: 
 
Zafirlukast 
 
20 mg 
 
Reference product B: 
 
Accolate 
 
20 mg 
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Table No. 2: Reference Standards: 
 
 
The reference standards of drug Zafirlukast and internal standard IS were procured. 
 
 
Compound Use 
          Zafirlukast Analyte 
IS Internal Standard 
 
 
 
Reagents and Chemicals 
 
Acetonitrile, Formic acid, Ammonium acetate, Methanol (HPLC Grade) and Milli-Q Water. 
 
 
 
 
 
Instrumentation 
 
Shimadzu HPLC equipped with pump, auto sampler, Mass spectrometer MDS SCIEX API 4000 
 
LC/MS/MS and data acquisition system (Analyst Software Version 1.4.1) were used  for the 
quantitative determination of analyte in human plasma. 
 
 
 
 
Method 
 
Method development 
 
The method development and establishment phase defines the chemical assay. Before beginning 
of the analysis for a molecule a method for its analysis has to be developed. The physico - 
chemical properties of the analyte play an important role in deciding various factors during the 
method development. The volume of reagents to be used, mobile phase compositions, extraction
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techniques,  various  spectroscopic  parameters  like  the  flow  rate,  split  ratio,  voltage,  gas 
parameters, parent and daughter ion masses etc are decided during the development phase. 
 
 
 
 
While developing an analytical method for drug Zafirlukast, it was found that the solid phase 
extraction technique was found to give better results during analysis. The resolution of the analyte 
peak and the peak shape were found to be good when 2mM Ammonium acetate and acetonitrile 
was used. C-18 cyano column was used. The masses of the parent and daughter ion were set during 
the tuning phase while setting the various potential and gas parameters. 
 
 
 
 
Method Validation 
 
The main objective of method validation is to demonstrate the reliability of a particular method 
for the quantitative determination of an analyte(s) concentration in a specific biological matrix. 
 
The fundamental parameters for a bioanalytical method validation are: 
 
 
  Accuracy, 
 
  Precision, 
 
  Selectivity, 
 
  Sensitivity, 
 
  Reproducibility, 
 
  Stability. 
 
 
 
 
In addition, the stability of the analyte in spiked samples should be determined. Typical method 
development and establishment for a bioanalytical method include determination of 
 
  selectivity, 
 
  accuracy, precision, recovery, 
 
  calibration curve, 
 
  stability of analyte in spiked samples.
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Selectivity is the ability of an analytical method to differentiate and quantify the analyte in the 
presence of other components in the sample. For selectivity, analyses of blank samples of the 
appropriate biological matrix (plasma, urine, or other matrix) should be obtained from at least six 
sources. Each blank sample should be tested for interference, and selectivity should be ensured at 
the lower limit of quantification (LLOQ). 
 
Accuracy of an analytical method describes the closeness of mean test results obtained by the 
method to the true value (concentration) of the analyte. 
 
Acceptance criteria: The mean value should be within 15% of the actual value except at LLOQ, 
where it should not deviate by more than 20%. 
 
Precision of an analytical method describes the closeness of individual measures of an analyte 
when the procedure is applied repeatedly to multiple aliquots of a single homogeneous volume of 
biological matrix. 
 
Acceptance criteria:  The precision determined at each concentration level should not exceed 15% 
of the coefficient of variation (CV) except for the LLOQ, where it should not exceed 20% of the 
CV. 
 
Recovery of an analyte in an assay is the detector response obtained from an amount of the analyte 
added to and extracted from the biological matrix, compared to the detector response obtained for 
the true concentration of the pure authentic standard. Recovery experiment was performed by 
comparing the analytical results for extracted samples at three concentrations (low, medium, and 
high) with unextracted standards that represent 100% recovery. 
 
 
 
 
Biological Matrix 
 
Human plasma containing Tri-potassium Ethylene Diamine Tetra Acetic acid (K3EDTA) as 
anticoagulant was procured from blood bank and chromatographically screened for interfering 
peaks prior to use. The batches free from endogenous interferences were pooled for bulk spiking
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of calibration curve   (CC) standards and the quality control (QC) samples. During  subject 
sample analysis, a pre-dose sample and pre-dose with IS of each subject in each period was used 
to check for interference from contaminants or endogenous compounds. 
 
 
 
 
Stock Solutions and Dilution Preparations 
 
The stock solution of drug Zafirlukast was prepared in a volumetric flask by dissolving the drug in 
methanol and final volume was made up using the same. The stock solution was diluted using a 
mixture of methanol and milli-Q-water to prepare calibration curve standards for spiking in 
plasma. The stock dilutions for quality control samples were prepared by diluting the stock  
solution  of drug  Zafirlukast  sodium  using  Methanol and  Milli-Q  water  mixture  for spiking 
in plasma. The stock solutions were stored between normal refrigerator temperatures. 
 
 
 
 
The stock solutions for IS (three different concentrations) were prepared in a volumetric flask, 
using methanol. Internal standard dilutions (three different concentrations) were prepared by 
diluting the above stocks with methanol and Milli-Q water mixture. The stock solutions of 
internal standard were stored between normal refrigerator temperatures. 
 
 
 
 
Preparation of Calibration Curve Standards 
 
To the screened human blank plasma, solutions of calibration standards (A, A1, B, C, D, E, F, G, 
H, and H1) of the drug Zafirlukast were added and the volume was made up with the same blank 
plasma. Aliquots were prepared using fixed volume of each standard and stored below 50oC.
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Preparation of Quality Control Samples 
 
The QC samples (LQC, MQC and HQC) were prepared by spiking drug Zafirlukast solutions to 
the screened human blank plasma and the volume was made up with the same blank plasma. 
Aliquots were prepared using fixed volume of each standard and stored below 50oC. 
 
Chromatographic Conditions 
 
Column C-18 Cyano column 
Mobile Phase Acetonitrile: 2mM Ammonium acetate 
Rinsing solution Acetonitrile: Milli-Q water 
Retention time Drug : 1.80 min – 2.20 min and IS: 1.80 min – 2.20 min 
 
 
 
Mass Spectrometric Parameters: 
 
Mass spectrometer API 4000 LC/MS/MS 
Ion source Electron spray ionization 
Polarity Positive 
Mass Transitions (Parent / Fragment) m/z 
Zafirlukast M1 m1 
IS M2, m2 
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Sample Processing & Extraction Technique 
 
Spiked plasma samples were retrieved from the deep-freezer and thawed in a water bath 
maintained at room temperature. The thawed samples were vortexed to ensure complete mixing 
of the contents. A fixed volume of IS dilution was added to prelabelled test tubes except in blank 
samples.  To these test  tubes the spiked  plasma  sample was added  and  vortexed.  This was 
followed by addition of 0.2% formic acid buffer and vortexed again. These samples were then 
extracted using the solid phase extraction technique. 
 
 
 
 
In solid phase extraction technique, SPE cartridge of 1 cc (30 mg) was used. The cartridges were 
conditioned on a Speed-disk
®  
pressure processor. using 1 mL each of methanol and Milli-Q 
water under constant positive pressure of 15 psi. Prepared plasma samples were loaded and 
followed by washing with Milli-Q water. The cartridges were dried under positive pressure and 
eluted with mobile phase. The eluent was centrifuged at 3220  50 RPM at 5C for 5 minutes. 
The clear supernatant was taken into vials and the samples were analyzed on LC/MS/MS. 
 
 
 
 
Subject sample analyses 
 
Subject Samples were processed along with QC samples (LQC, MQC and HQC). During subject 
sample analysis, with each CC, samples of two subjects were analyzed in 8 batches and samples 
of single subject were analyzed in 10 batches. 
 
 
 
 
Identified repeats were analyzed in 2 batches. In all the cases, batch was rejected or accepted 
based on the results obtained for QCs run with that particular batch The subject samples were 
analyzed within 3 freeze thaw cycles
17
.
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Data Collection 
 
All  data  collection  and  integration  (area  mode)  were  performed  by  Analyst  version  1.4.1 
software systems. The intercepts and goodness of fit were determined by least squares linear 
regression analyses using the ratios of drug / internal standard peak areas of the CC standards. 
The concentrations of all the study samples, CC standards and QC samples were calculated by 
Analyst version 1.4.1 software systems. A weighting factor of 1/(concentration)
2 
was used in the 
calculation of linear regression line with the following equation. 
 
y = mx + b 
 
 
Where, y = peak area ratio of analyte / internal standard 
m = slope of the CC 
x = concentration ratio of analyte / internal standard 
b = y-axis intercept of the CC
AN OPEN LABEL TWO WAY TWO PERIOD RANDOMISED SINGLE DOSE COMPARITIVE ORAL BIOAVAILABILITY STUDY OF 
ZAFIRLUKAST IN HEALTHY VOLUNTEERS UNDER FASTING CONDITIONS 
57 
 
 
 
 
Statistical Interpretation 
 
 
 
There is a growing need of the application of mathematical statistics to a wide range of 
biological  processes.  Most  people  working  in  scientific  research  are  forced  to  apply  some 
concepts of biostatistics into their work if they want to share their results with the scientific 
community. This community needs to be convinced in order to trust your approach. And this is 
mostly done by biostatistics in forms of significance tests, confidence intervals and so on. A 
researcher is forced to show that his experimental outcome is not just a matter of chance for 
convincing other researcher to apply his methodology. 
 
The following figure illustrates the statistical thinking process based on data in constructing 
statistical models for decision-making under uncertainties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The above figure depicts the fact that as the exactness of a statistical model increases, the level of 
improvements in decision-making increases. That's why we need statistical data analysis.
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The post study data obtained is analyzed using various statistical tools like the t -test, ANNOVA 
 
and the software like SAS and WinNonlin. 
 
 
Analysis Of Variance (ANOVA), a calculation procedure to allocate the amount of variation in 
a process and determine if it is significant or is caused by random noise. Using this statistical tool 
different parameters like the formulation effect, sequence affect, treatment effect between the test 
product and the reference product can be analysed. Based on the results obtained in this test the 
bioequivalence between the two products can be determined. 
 
WinNonlin
®  
is the industry standard for pharmacokinetic, pharmacodynamic, and 
noncompartmental analysis. In addition to its extensive library of built -in PK, PD and PK/PD 
models, WinNonlin supports custom, user-defined models to address any kind of data. 
 
WinNonlin provides a complete solution with data management, statistical, modeling, and 
visualization tools in one package. Its worksheet interface facilitates data handling and 
transformations.  Its descriptive statistics and  linear  mixed  effects modeling  engines provide 
flexible pre- and post-modeling analyses. The bioequivalence wizard supports FDA standards for 
average, individual and population bioequivalence assessment. Additional tools enable exploration 
of your drug’s properties through non-parametric superposition, semicompartmental modeling, 
deconvolution and nonparametric analysis of crossover studies. Finally, WinNonlin chart and table 
wizards, and automatic chart output from modeling, produce high-quality output for your study 
reports. 
 
Statistical analysis software (SAS
®
) - includes a vast range of statistics for general statistical 
analysis which includes multiple linear regression, correlation, ANOVA (analysis of variance), 
chi-square, Fisher, McNemar, Wilcoxon, Mann-Whitney, Friedman, Kruskal Wallis, Shapiro- 
Wilk normality tests, histograms, summary statistics and many more. 
 
With the help of these softwares the PK parameters and statistical results are calculated for the 
data obtained after the completion of the study
18
.
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Results and Discussion 
 
The Zafirlukast plasma concentration of 12 individual subjects in the given study reports as 
follows: 
 
 Linear plot mean of individual plasma Zafirlukast conc vs time under fasting conditions
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Linear mean plot of plasma Zafirlukast conc vs time under fasting conditions
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Semilog mean plot of plasma Zafirlukast conc vs time under fasting conditions
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    Zafirlukast 
    Time 
Treatment Subject Period Sequence 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 6.00 8.00 10.00 12.00 16.00 20.00 24.00 
R 1 2 TR 0.00 53.48 231.93 416.88 482.62 425.54 441.07 526.11 522.68 418.10 413.07 361.43 228.96 146.70 100.66 47.08 21.07 11.95 
 2 1 RT 0.00 0.00 14.98 49.40 73.19 101.46 147.27 250.22 371.75 394.68 386.31 290.12 193.11 110.81 74.06 32.99 19.80 15.33 
 3 2 TR 0.00 8.02 43.16 59.18 75.27 77.13 133.70 258.89 350.84 361.75 448.30 368.20 224.07 129.44 74.09 24.12 13.40 8.15 
 4 1 RT 0.00 11.67 211.56 321.43 525.91 653.63 561.08 537.02 435.30 356.56 311.70 223.75 127.55 71.93 39.89 17.23 8.52 6.73 
 5 2 TR 0.00 74.09 182.59 436.97 653.66 646.32 585.61 512.70 503.42 403.35 332.84 288.75 193.27 123.30 98.50 46.51 27.79 20.41 
 6 1 RT 0.00 33.06 192.57 265.93 336.77 317.09 324.91 341.91 316.12 319.13 299.96 237.78 191.80 86.67 63.24 26.86 14.27 8.42 
 7 1 RT 0.00 41.03 236.59 318.31 411.17 562.05 617.86 567.97 521.19 453.46 403.18 332.92 242.88 166.44 106.73 57.76 34.86 25.35 
 8 2 TR 0.00 0.00 2.68 9.85 20.11 33.22 58.99 129.92 231.41 270.65 302.76 298.56 208.43 127.73 87.64 39.02 25.60 15.26 
 9 1 RT 0.00 0.00 2.10 4.94 8.27 9.69 13.46 36.89 54.56 171.36 304.34 569.75 549.35 370.25 217.88 101.11 63.08 43.07 
 10 2 TR 0.00 10.38 80.53 127.28 173.15 192.30 236.62 268.75 316.04 271.51 240.65 202.69 145.81 94.31 63.42 31.29 16.62 8.98 
 11 1 RT 0.00 34.34 148.54 196.81 297.21 331.22 410.37 456.80 447.86 432.06 348.84 308.03 186.54 103.40 96.32 34.85 19.13 11.45 
 12 2 TR 0.00 0.00 0.00 12.82 68.11 109.56 177.41 206.98 202.24 200.20 189.54 153.99 99.93 62.93 39.35 16.65 10.69 6.81 
   N 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 
   Mean 0.00 22.17 112.27 184.98 260.45 288.27 309.03 341.18 356.12 337.73 331.79 303.00 215.98 132.83 88.48 39.62 22.90 15.16 
   SD 0.000 24.705 97.394 162.544 221.496 237.687 211.642 176.403 143.026 91.976 73.914 105.714 113.158 80.554 46.557 22.926 14.697 10.480 
   Min 0.00 0.00 0.00 4.94 8.27 9.69 13.46 36.89 54.56 171.36 189.54 153.99 99.93 62.93 39.35 16.65 8.52 6.73 
   Median 0.00 11.03 114.54 162.05 235.18 254.70 280.77 305.33 361.30 359.16 322.27 294.34 193.19 117.06 80.87 33.92 19.47 11.70 
   Max 0.00 74.09 236.59 436.97 653.66 653.63 617.86 567.97 522.68 453.46 448.30 569.75 549.35 370.25 217.88 101.11 63.08 43.07 
   CV% Missing 111.42 86.75 87.87 85.04 82.45 68.49 51.70 40.16 27.23 22.28 34.89 52.39 60.65 52.62 57.86 64.17 69.13 
                      
T 1 1 TR 0.00 177.62 592.10 727.76 680.82 644.39 541.38 466.49 443.10 365.55 340.78 249.58 167.54 106.92 77.01 30.18 19.04 12.28 
 2 2 RT 0.00 0.00 11.33 19.90 34.32 77.47 144.52 251.70 349.81 392.61 357.47 351.97 239.65 154.63 118.33 54.56 30.42 21.28 
 3 1 TR 0.00 33.13 170.49 279.19 319.00 398.56 449.12 476.59 436.70 344.48 275.87 235.04 109.07 62.26 46.63 14.83 7.76 5.05 
 4 2 RT 0.00 7.37 184.94 399.74 493.31 505.44 472.97 450.98 455.79 353.19 293.37 251.96 137.72 79.64 64.80 27.63 14.16 8.86 
 5 1 TR 0.00 181.77 386.67 388.92 416.01 403.88 426.03 444.10 395.83 374.91 322.61 278.44 184.25 101.24 68.37 33.41 19.32 13.08 
 6 2 RT 0.00 115.27 275.67 350.03 365.68 337.36 318.61 386.60 414.31 373.08 278.68 235.75 161.82 85.89 51.89 22.08 12.44 8.35 
 7 2 RT 0.00 88.43 354.08 374.63 485.82 430.18 433.82 415.06 454.79 342.10 360.22 271.03 217.37 149.05 95.67 58.05 40.57 28.48 
 8 1 TR 0.00 3.68 21.56 33.67 68.95 218.33 402.26 600.97 533.66 493.58 475.27 430.17 280.16 152.77 131.53 64.93 39.31 29.46 
 9 2 RT 0.00 0.00 9.47 25.44 43.83 44.25 60.37 105.92 203.40 403.94 451.41 493.86 441.58 339.40 220.39 120.40 73.10 48.27 
 10 1 TR 0.00 11.93 88.68 202.28 247.07 242.97 241.15 242.01 248.03 216.86 198.39 172.37 126.87 78.36 51.53 26.48 13.86 9.33 
 11 2 RT 0.00 235.32 518.99 681.70 577.15 621.40 510.99 482.73 414.01 408.71 323.21 281.83 222.69 148.85 103.83 49.10 28.14 19.41 
 12 1 TR 0.00 5.34 51.37 120.36 185.46 199.57 214.27 218.36 204.36 258.14 207.11 188.23 104.77 65.62 42.46 18.48 10.26 6.53 
   N 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 
   Mean 0.00 71.66 222.11 300.30 326.45 343.65 351.29 378.46 379.48 360.60 323.70 286.69 199.46 127.05 89.37 43.34 25.70 17.53 
   SD 0.000 85.703 202.992 237.721 215.108 194.242 153.851 142.488 106.639 70.777 83.438 94.731 93.660 75.576 50.536 29.334 18.527 12.705 
   Min 0.00 0.00 9.47 19.90 34.32 44.25 60.37 105.92 203.40 216.86 198.39 172.37 104.77 62.26 42.46 14.83 7.76 5.05 
   Median 0.00 22.53 177.72 314.61 342.34 367.96 414.15 429.58 414.16 369.32 322.91 261.50 175.90 104.08 72.69 31.80 19.18 12.68 
   Max 0.00 235.32 592.10 727.76 680.82 644.39 541.38 600.97 533.66 493.58 475.27 493.86 441.58 339.40 220.39 120.40 73.10 48.27 
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  Tmax Cmax AUClast AUCINF_obs Lambda_z        HL_Lambda_AzUC_%Extrap_o Rsq 
  Treatment Treatment Treatment Treatment Treatment Treatment Treatment Treatment 
 
Subject 
 
Sequence 
 
R 
 
T 
 
R 
 
T 
 
R 
 
T 
 
R 
 
T 
 
R 
 
T 
 
R 
 
T 
 
R 
 
T 
 
R 
 
T 
1 TR 3.50 1.50 526.11 727.76 3960.95 3950.95 4023.44 4060.20 0.1912 0.1124 3.62 6.17 1.55 2.69 0.9976 0.9998 
 
2 
 
RT 
 
4.50 
 
4.50 
 
394.68 
 
392.61 
 
2498.23 
 
2962.92 
 
2583.69 
 
3096.98 
 
0.1794 
 
0.1587 
 
3.86 
 
4.37 
 
3.31 
 
4.33 
 
0.9716 
 
0.9910 
 
3 
 
TR 
 
5.00 
 
3.50 
 
448.30 
 
476.59 
 
2668.17 
 
2596.10 
 
2728.26 
 
2617.73 
 
0.1356 
 
0.2336 
 
5.11 
 
2.97 
 
2.20 
 
0.83 
 
0.9977 
 
0.9779 
 
4 
 
RT 
 
2.50 
 
2.50 
 
653.63 
 
505.44 
 
3011.57 
 
3073.83 
 
3040.65 
 
3125.35 
 
0.2314 
 
0.1720 
 
3.00 
 
4.03 
 
0.96 
 
1.65 
 
0.9729 
 
0.9892 
 
5 
 
TR 
 
2.00 
 
3.50 
 
653.66 
 
444.10 
 
3948.77 
 
3381.85 
 
4069.01 
 
3453.55 
 
0.1697 
 
0.1824 
 
4.08 
 
3.80 
 
2.96 
 
2.08 
 
0.9823 
 
0.9838 
 
6 
 
RT 
 
3.50 
 
4.00 
 
341.91 
 
414.31 
 
2733.41 
 
2836.81 
 
2791.47 
 
2905.51 
 
0.1450 
 
0.1216 
 
4.78 
 
5.70 
 
2.08 
 
2.36 
 
0.9973 
 
0.9893 
 
7 
 
RT 
 
3.00 
 
2.00 
 
617.86 
 
485.82 
 
4226.59 
 
3837.46 
 
4384.69 
 
4157.41 
 
0.1603 
 
0.0890 
 
4.32 
 
7.79 
 
3.61 
 
7.70 
 
0.9860 
 
1.0000 
 
8 
 
TR 
 
5.00 
 
3.50 
 
302.76 
 
600.97 
 
2277.57 
 
3926.37 
 
2407.60 
 
4114.23 
 
0.1174 
 
0.1568 
 
5.91 
 
4.42 
 
5.40 
 
4.57 
 
0.9965 
 
0.9808 
 
9 
 
RT 
 
6.00 
 
6.00 
 
569.75 
 
493.86 
 
4469.26 
 
4621.33 
 
4873.01 
 
5043.82 
 
0.1067 
 
0.1143 
 
6.50 
 
6.07 
 
8.29 
 
8.38 
 
0.9963 
 
0.9972 
 
10 
 
TR 
 
4.00 
 
4.00 
 
316.04 
 
248.03 
 
2202.90 
 
2022.91 
 
2260.45 
 
2077.57 
 
0.1560 
 
0.1707 
 
4.44 
 
4.06 
 
2.55 
 
2.63 
 
0.9999 
 
0.9923 
 
11 
 
RT 
 
3.50 
 
1.50 
 
456.80 
 
681.70 
 
3208.94 
 
4293.00 
 
3291.24 
 
4410.43 
 
0.1391 
 
0.1653 
 
4.98 
 
4.19 
 
2.50 
 
2.66 
 
0.9980 
 
0.9926 
 
12 
 
TR 
 
3.50 
 
4.50 
 
206.98 
 
258.14 
 
1428.55 
 
1762.47 
 
1489.49 
 
1812.69 
 
0.1118 
 
0.1300 
 
6.20 
 
5.33 
 
4.09 
 
2.77 
 
1.0000 
 
0.9943 
 N 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 
 
 
Mean 
 
3.83 
 
3.42 
 
457.37 
 
477.44 
 
3052.91 
 
3272.17 
 
3161.92 
 
3406.29 
 
0.1536 
 
0.1506 
 
4.73 
 
4.91 
 
3.29 
 
3.55 
 
0.9913 
 
0.9907 
 
 
SD 
 
1.135 
 
1.346 
 
148.959 
 
145.783 
 
932.091 
 
889.537 
 
993.516 
 
978.740 
 
0.03608 
 
0.03921 
 
1.067 
 
1.333 
 
1.967 
 
2.330 
 
0.01044 
 
0.00703 
 
 
Min 
 
2.00 
 
1.50 
 
206.98 
 
248.03 
 
1428.55 
 
1762.47 
 
1489.49 
 
1812.69 
 
0.1067 
 
0.0890 
 
3.00 
 
2.97 
 
0.96 
 
0.83 
 
0.9716 
 
0.9779 
 
 
Median 
 
3.50 
 
3.50 
 
452.55 
 
481.21 
 
2872.49 
 
3227.84 
 
2916.06 
 
3289.45 
 
0.1505 
 
0.1578 
 
4.61 
 
4.39 
 
2.75 
 
2.68 
 
0.9969 
 
0.9917 
 
 
Max 
 
6.00 
 
6.00 
 
653.66 
 
727.76 
 
4469.26 
 
4621.33 
 
4873.01 
 
5043.82 
 
0.2314 
 
0.2336 
 
6.50 
 
7.79 
 
8.29 
 
8.38 
 
1.0000 
 
1.0000 
 
 
CV% 
 
29.60 
 
39.38 
 
32.57 
 
30.53 
 
30.53 
 
27.18 
 
31.42 
 
28.73 
 
23.48 
 
26.04 
 
22.55 
 
27.16 
 
59.77 
 
65.57 
 
1.05 
 
0.71 
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Safety and Efficacy 
 
The safety criteria included in the study were presence or absence of adverse events, 
adverse drug reactions and also any changes in the physical or biochemical parameters after 
completion of the study when compared with pre study values. 
 
During post study assessment vitals and medical examination for all the subjects participating in 
the study were normal, however a few of them had abnormal values in the medical reports. These 
cases were reported as adverse events. The following table provides a list of adverse events 
occurred in the subjects and the treatment given to them. 
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S7 
 
 
 
Post study 
 
 
 
 
T 
Increased 
 
SGOT (100 U/L) 
Increased 
 
SGPT (116 U/L) 
 
 From the adverse events profile and tolerability of the subjects, it appeared that the test 
product was safe and tolerable as that of reference product. 
 No deaths and serious adverse events were reported during the entire duration of the 
study
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ABNORMAL LABORATORY VALUE LISTING (Each Subject) 
Listing of Abnormal Hematology Laboratory Values 
 
 
 
 
 
 
Parameter 
 
 
 
Subject Number 
Pre/Post study 
 
 
 
Remarks  
S 
 
P 
 
 
 
 
 
Total RBC 
(mill/cumm) 
S1 6.25 
H
 -- CNS 
S5 -- 4.4 
L
 CNS 
S9 --- 6.0 
H
 CNS 
S7 4.1 
L
 4.3 
L
 CNS 
S11 6.06 
H
 4.8 
L
 CNS 
 
 
 
Haemoglobin (gm/dL) 
S1 -- 12.5 
L
 CNS 
S5 12.3 
L
 12.2 
L
 CNS 
S12 -- 12.4 
L
 CNS 
Total WBC (cells/cumm) S3 11700 
H
 -- CNS 
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S: Pre-study (screening) evaluation; P: Post study evaluation. 
WBC: Leukocytes; 
RBC: Erythrocytes 
 
L
: Lower than normal range; 
H
: Higher than normal range. 
CNS: Clinically not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Listing of Abnormal Biochemistry Laboratory Values 
 
 
Parameter 
 
Subject Number 
Pre/Post Study  
Remarks 
S P 
Uric Acid(mg/dL) S2 7.5 
H
 -- CNS 
 
 
 
Urea (mg/dL) 
S2 44 
H
 -- CNS 
S4 14 
L
 -- CNS 
S9 -- 16 
L
 CNS 
 
 
 
Total Protein (g/Dl) 
S1 8.7 
H
 -- CNS 
S3 8.6 
H
 -- CNS 
S7 8.5 
H
 -- CNS 
Total cholesterol(mg/dL) S2 211 
H
 -- CNS 
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 S7 220H -- CNS 
Calcium(mg/dL) S1 10.7 
H
 -- CNS 
Sodium(mmol/L) S5 134 
L
 -- CNS 
SGOT S7 -- 100 
H
 CS 
 
SGPT 
S2 -- 46 
H
 CNS 
S7 -- 116 
H
 CS 
 
 
 
 
 
S: Pre-study (screening) evaluation; P: Post study evaluation. 
S: Pre-study (screening) evaluation; P: Post study evaluation. 
SGOT: Serum Glutamate Oxaloacetate Transaminase 
SGPT: Serum Glutamate Pyruvate Transaminase 
 
L
: Lower than normal range; 
H
: Higher than normal range. 
CNS: Clinically not significant. 
Calibration Curve Standards Data 
 
A total of 25 CCs were run for the bioanalysis of subject  plasma samples containing drug 
Zafirlukast .  The slopes,  intercepts and  goodness of fit  were determined  by Linear regression 
analyses using the ratios of drug / internal standard peak areas of the CC standards. A weighting 
factor of 1/x
2  
(1/ concentration
2
) was used in the calculation of the linear regression line and the 
concentrations of all the study samples and QC samples were calculated by Analyst 
1.4.1  software  system.  The  Regression  coefficient  (r
2
)  was  greater  than  0.99  for  drug 
 
Zafirlukast throughout the study.
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Quality Control Samples Data 
 
A total of 116 sets of QC samples at 3 different concentrations (LQC, MQC & HQC) of drug 
Zafirlukast were analyzed, interspersed with the subject samples. 
 
Subject Sample Analyses Data 
 
A total of 12 subject samples were analysed as per the validated method. The QC samples were 
dispersed throughout the subject run to control and monitor precision of batch inter-assay variation. 
 
Stability of the stock solutions in the matrix 
 
The stock solutions of the drug as well as the  reference standards were found to be stable. 
Benchtop stability, Freeze-thaw stability and long term stabilities were determined.Long-term 
stability was determined for a period of 3 months. 
 
Pharmacokinetic parameters and statistical Data 
 
Pharmacokinetic parameters and statistical analyses were calculated from subject concentrations 
using   validated   WinNonlin
®    
Version  5.1   and   SAS
®    
Version  9.1   software   procedures, 
respectively.
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Pharmacokinetic Data 
 
The following table summarizes the pharmacokinetic results obtained  for test and reference 
formulations of drug Zafirlukast in the fasting condition. 
 
 
 
 
 
PK PARAMETERS 
 
 
 
DRUG 
ZAFIRLUKAST (TEST) ACCOLATE 
 
(REFERENCE) 
 
 
 
Cmax (µg/mL) 
Mean 
SD 
CV% 
 
 
 
 
 
477.44 
 
148.959 
 
32.57 
 
 
 
 
 
457.37 
 
145.783 
 
30.53 
 
 
 
AUC0-t (µg.hr/mL) 
Mean 
SD 
CV% 
 
 
 
 
 
3272.17 
 
889.537 
 
27.18 
 
 
3052.91 
 
932.091 
 
30.53 
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AUC0- (µg.hr/mL) 
Mean 
SD 
CV% 
 
 
 
3406.29 
 
 
978.740 
 
 
28.73 
 
 
 
3161.92 
 
 
993.51 
 
 
31.42 
AUC_Extrapolated (%) 
 
 
Mean 
SD 
CV% 
 
 
3.55 
 
2.330 
 
65.57 
 
 
3.29 
 
1.960 
 
59.77 
Tmax (hr) 
 
 
Mean 
SD 
Median 
CV% 
 
 
 
3.42 
 
1.346 
 
3.50 
 
39.38 
 
 
 
3.83 
 
1.135 
 
3.50 
 
29.60 
Kel (hr
-1
) 
 
Mean 
SD 
CV% 
 
 
 
0.1506 
 
0.03921 
 
26.04 
 
 
 
0.1536 
 
0.03608 
 
23.48 
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ZAFIRLUKAST 90% CONFIDENCE INTERVAL DATA 
 
 
 
 
 
 
 
 
Dependent 
 Test 
                           T   
 
  CI_90_Lower    CI_90_Upper   
97.59               120.53 
97.09               120.48 
88.42               125.19 
 
 
  Ratio[%Ref]   
 
Power 
Ln(AUCINF_obs)        108.46 
Ln(AUClast)            108.15 
Ln(Cmax)              105.21 
0.96 
0.96 
0.69 
 
 
No statistically significant differences were observed for sequence and formulation effects for ln- 
transformed Cmax, AUC0-t & AUC0- data of the Test and Reference Product. 
 
Intra-subject Variability: 
 
 
The coefficients of variation (CV%) corresponding to intra-subject variability for Cmax, AUC0-t 
 
and AUC0- were 30.53 %, 27.18 % and 28.73 %, respectively, which were found to be less than 
 
30%. 
 
 
Power: 
 
 
The power values obtained for Cmax, AUC0-t and AUC0-  were 88.42 %, 97.09 % and 97.59 %, 
respectively, which were greater than 80.00 % the desired power to support the bioequivalence 
test, and hence considered to be adequate for supporting bioequivalence conclusions.
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CONCLUSION 
 
All the study procedures followed were in compliance with the protocol and the ICH- 
GCP guidelines, Declaration of Helsinki and Schedule Y. 
 
From the results obtained, in both the fast and the fed study, it is observed that there is no 
significant difference in the pharmacokinetic parameters, indicating that the bioavailability of 
drug XY is not affected by food. 
 
From the analyses of pharmacokinetic and statistical results it was inferred that, for the ln- 
transformed data, the 90 % confidence interval about the test to reference ratio of Cmax, AUC0-t 
and AUC0-  of drug XY were falling within the bioequivalence acceptance range of 80.00 % - 
125.00 %, which demonstrates the bioequivalence of test formulation ‘ZAFIRLUKAST’ with 
reference formulation ‘SINGULIAR’ under fasting conditions. 
 
From the clinical data it can be concluded that the study objectives like the safety and efficacy of 
the test product has been achieved. 
 
 
 
 
Based on clinical, pharmacokinetic and statistical data obtained from healthy, adult, male, 
human subjects under fasting conditions, it was concluded that a single dose of test 
formulation ‘ZAFIRLUKAST’ containing drug  1000 mg was found to be safe and 
bioequivalent to the reference formulation ‘ACCOLATE’ containing drug 1000 mg as 
90 % confidence interval for the ratios of means of test and reference parameters such as 
ln-transformed Cmax, AUC0-t  and AUC0-  of drug is within the bioequivalence acceptance 
range of 80.00% – 125.00 %.
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GLOSSARY 
 
 
 
 
1. Adverse  Event:  An  adverse  event  is  any  untoward  medical  occurrence  in  clinical 
investigation subject administered a pharmaceutical product and that does not necessarily 
have a causal relationship with this treatment. 
 
 
 
2. Analysis of Variance (ANOVA): ANOVA is a statistical technique to identify sources 
of variance and estimate the degree of variability. In most bioavailability studies, there 
are three readily identified sources of variance namely formulation (Treatment), subject 
and period; hence it is a 3-way ANOVA. 
 
 
 
3. Area under the curve (AUC): Area under the curve is the total area under the biological 
fluid  (serum,  blood,  etc.)  concentration-time curve as determined  by the Trapezoidal 
rule. 
 
 
 
4.         AUC_Extrapolated (%): Calculated as {1 - (AUC0-t / AUC0-)} x 100. The mean 
 
AUC_Extrapolated (%) should be ≤ 20%. 
 
 
 
 
5. Bioavailability  studies:  It involves the determination of ‘Drug’ concentration in the 
blood or urine. Concern with how quickly and how much of a ‘Drug’ appears in the 
blood after a specific dose is administered. 
 
 
 
6. Cmax:  This  is  the  maximum  ‘Drug’  concentration  achieved  in  systemic  circulation 
following ‘Drug’ administration 
 
 
 
7. Good Clinical Practice: A standard for the design, conduct, performance, monitoring, 
auditing, recording, analyses and reporting of clinical trials that provides assurance that
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the data and reported results are credible and accurate, and that the rights, integrity, and 
confidentiality of trial subjects are protected. 
 
 
 
8. Informed  Consent:  A  process  by  which  a  subject  voluntarily  confirms  his  or  her 
willingness to participate in a particular trial, after having been informed of all aspects of 
the trial are relevant to the subject’s decision to participate. Informed consent is 
documented by means of a written, signed, and dated informed consent form. 
 
 
 
9. Investigational Product: A pharmaceutical form of an active ingredient being tested or 
used as a reference in a clinical trial, including a product with a marketing authorization 
when used or assembled (formulated or packaged) in a way different from the approved 
form,  or  when  used  for  an  unapproved  indication,  or  when  used  to  gain  further 
information about an approved use. 
 
 
 
10. Kel: Apparent first-order terminal elimination rate constant calculated from a semi-log 
plot of the plasma concentration versus time curve, using the method of least square 
regression. 
 
 
 
11. Protocol: A document that describes the objective(s), design, methodology, statistical 
consideration, and organization of a trial. The protocol usually also give the background 
and  rationale  for  the trial,  but  these could  be  provided  in other  protocol referenced 
documents. Throughout the ICH-GCP Guidance, the term protocol refers to protocol and 
protocol amendments. 
 
 
 
12. Quality  Assurance:  All those planned  and  systematic action that  are established  to 
ensure that the trial is performed and the data are generated, documented (recorded), and 
reported in compliance with GCP and the applicable regulatory requirements(s).
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13. Quality Control: The operational techniques and activities undertaken within the quality 
assurance system to verify that the requirements for quality of the trial related activities 
have been fulfilled. 
 
 
 
14. Randomization:  The process of assigning trial subject to treatment  groups using an 
element of chance to determine the assignments in order to reduce bias. 
 
 
 
15. Sponsor-Investigator:  An  individual  who  both  initiate  and  conducts,  alone  or  with 
others, a clinical trial and under whose immediate direction the investigational product is 
administered to, dispensed to, or used by a subject. The term does not include any person 
other  than  an  individual (e.g.  it  does  not  include  a  corporation  or  an  agency).  The 
obligations of a sponsor-investigator include both those a sponsor and those of an 
investigator. 
 
 
 
16.       Tmax:  It  is the time required  to  achieve  maximum ‘Drug’ concentration  in systemic 
 
circulation 
 
 
 
 
17.       t1/2: Terminal half-life as determined by quotient 0.693/ Kel
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